Article
Inhalation Drug Products — MDI and DPI CMC Under OGD Product-Specific Guidance and ICH Q4B
The FDA product-specific guidance for your MDI reference listed drug tells you the exact cascade impactor, the exact flow rate, the exact stage mass acceptance criteria, and the…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Inhalation Drug Products — MDI and DPI CMC Under OGD Product-Specific Guidance and ICH Q4B
The FDA product-specific guidance for your MDI reference listed drug tells you the exact cascade impactor, the exact flow rate, the exact stage mass acceptance criteria, and the…
Article
Ophthalmic Drug Products — CMC Requirements for Sterile Ophthalmic Solutions, Suspensions, and Ointments
Ophthalmic drug products are sterile, but they are not parenterals. The endotoxin limits that govern every injectable drug product do not apply to topical ophthalmic products.
Article
Implantable Drug Delivery Systems — CMC for Subcutaneous Implants, Pellets, and Reservoir Devices
An implant that delivers drug for one year or three years requires an in vitro drug release test that runs for one year or three years at real-time…
Article
Ready-to-Use Parenteral Preparation — Pre-Filled Bags, Admixture Stability, and the CMC Package
A ready-to-use parenteral product in a pre-filled IV bag seems simpler than a vial requiring reconstitution and dilution. The bag is pre-filled, the drug is pre-dissolved, the nurse…
Article
Injectable Drug Product Container Closure — Stopper Qualification, CCI Testing, and Extractables Evidence
Your container closure system passed compatibility testing. Your stopper vendor provided a Masterfile. Your vial meets USP container standards. And then CDER opens your 3.2.P.7 section and finds…
Article
Particle Identification in Injectables — Visible and Sub-Visible Particles, USP 788-787, and CMC Control
Your USP sub-visible particle test is compliant. Every batch passes ≥10 μm ≤6,000 and ≥25 μm ≤600 particles per container. What FDA will ask for in your BLA…
Article
Autoinjector and Pen Injector CMC — Human Factors, Functional Testing, and the Combination Product Package
An autoinjector that delivers 98% dose accuracy at room temperature can fail the same accuracy standard at refrigerator temperature with the identical formulation, and the physics behind that…
Article
Prefilled Syringe CMC — Device-Drug Combination Regulatory Strategy Under 21 CFR Part 3 Combination Products
The prefilled syringe is simultaneously a container closure system and a drug delivery device. How you define it in your NDA determines the entire CMC regulatory pathway.
Article
Extractables and Leachables for Injectable Drug Products: Building a Risk-Based Primary-Packaging CMC Strategy
Extractables and leachables are not a residual-solvent problem. They are a product-contact materials problem that must be controlled through an integrated assessment of packaging components, manufacturing-system contact materials,…
Article
Lyophilization Scale-Up and Technology Transfer — CPP Mapping and the CMC Comparability Evidence Package
The shelf temperature setpoint that produced a perfect lyophilized cake in your development lyophilizer will not necessarily produce a perfect cake in your commercial lyophilizer.
Article
Lyophilization CMC — Cycle Development, Design Space, and the Regulatory Submission Package
Your lyophilization cycle has a primary drying shelf temperature of −30°C. Your FDA reviewer has one question before accepting that cycle as scientifically justified: what is your formulation's…
Article
Parenteral Formulation Development — pH, Osmolality, Tonicity, and Compatibility CMC Package
pH 5.5 is a formulation design decision. It is also a clinical tolerability decision and a regulatory documentation decision.
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.